HCM
REGN icon

Hollencrest Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hollencrest Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39K Hold
7
– – ﹤0.01% 933
2026
Q1 		$5.44K Hold
7
– – ﹤0.01% 908
2025
Q4 		$5.43K Hold
7
– – ﹤0.01% 898
2025
Q3 		$3.95K Hold
7
– – ﹤0.01% 924
2025
Q2 		$3.68K Hold
7
– – ﹤0.01% 901
2025
Q1 		$4.44K Sell
7
-1
-13% -$688 ﹤0.01% 889
2024
Q4 		$5.7K Hold
8
– – ﹤0.01% 873
2024
Q3 		$8.41K Buy
8
+1
+14% +$1.11K ﹤0.01% 783
2024
Q2 		$7.36K Sell
7
-100
-93% -$96.9K ﹤0.01% 781
2024
Q1 		$103K Sell
107
-232
-68% -$221K ﹤0.01% 362
2023
Q4 		$298K Sell
339
-13
-4% -$10.7K 0.03% 247
2023
Q3 		$290K Hold
352
– – 0.03% 234
2023
Q2 		$253K Hold
352
– – 0.03% 263
2023
Q1 		$289K Buy
352
+345
+4,929% +$260K 0.03% 238
2022
Q4 		$5.05K Buy
+7
New +$5.17K ﹤0.01% 827

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hollencrest Capital Management's REGN Position: Q2 2026 in Review

Hollencrest Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 7 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Hollencrest Capital Management first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $298K in Q4 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hollencrest Capital Management held 7 shares of Regeneron Pharmaceuticals worth $4.39K as of Q2 2026.
  • Hollencrest Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #933 holding.
  • Hollencrest Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Hollencrest Capital Management's Regeneron Pharmaceuticals position peaked at $298K in Q4 2023.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.